• ABT-199 (Venetoclax) Workflow for Apoptosis Research

  2026-08-25

  Build more interpretable apoptosis and viability experiments with ABT-199, a highly selective BCL-2 probe for hematologic malignancy models. This workflow connects dose design, mitochondrial pathway readouts, and combination testing to practical troubleshooting insights from DLBCL research.

• VX-765: Translational Control of Pyroptosis

  2026-08-25

  A mechanistic and strategic guide to using VX-765 and its active metabolite VRT-043198 to distinguish caspase-1-driven cytokine maturation from broader inflammatory signaling and to strengthen translational pyroptosis studies.

• Cyclosporin A: Assays, Workflows, and Optimization

  2026-08-24

  Cyclosporin A enables controlled interrogation of calcineurin–NF-AT signaling, T-cell activation, and cyclophilin-dependent mitochondrial responses. This practical guide separates pharmacologic effects from genetic background, with executable assay parameters and troubleshooting strategies for reproducible immunology and cell biology workflows.

• Pseudo-UTP: A Strategic Lever for Better RNA

  2026-08-24

  A mechanistic and translational guide to using Pseudo-UTP as a design variable in RNA synthesis, mRNA vaccine development, and gene therapy research.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-23

  Phosbind Acrylamide adds a practical, antibody-independent layer to phosphorylation studies by converting phosphate-dependent binding into an SDS-PAGE mobility shift. It is especially useful for mapping treatment-responsive signaling changes, validating kinase or phosphatase activity, and testing phosphorylation hypotheses alongside apoptosis and phase-separation assays.

• TAI-1: From RB1 Organoids to Mitotic Assays

  2026-08-22

  TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied in more informative, genotype-aware cancer models. This article connects RB1-deficient retinal organoid findings with practical assay design while distinguishing established evidence from testable hypotheses.

• Lisinopril Dihydrate: ACE Inhibitor Research Guide

  2026-08-22

  Lisinopril dihydrate is a water-soluble, long-acting ACE inhibitor used to modulate renin–angiotensin signaling in hypertension research and related cardiovascular and renal models. Its catalog-reported IC50 is 4.7 nM, while formulation, storage, and assay-specific exposure must be controlled independently.

• BCL9–β-Catenin Inhibition Restores PD-1 Response

  2026-08-21

  Feng et al. developed hydrocarbon-stapled peptides that disrupt the β-catenin–BCL9 interaction, suppress oncogenic Wnt transcription, and remodel the tumor immune microenvironment. In preclinical models, the lead peptide reduced regulatory T cells, increased dendritic-cell and cytotoxic T-cell activity, and sensitized tumors to PD-1 blockade, supporting a targeted strategy for overcoming immune checkpoint resistance.

• Arsenic, BBB Disruption, and MMP-2/MMP-9 in Mice

  2026-08-20

  The reference study links sodium arsenite exposure to cognitive impairment through MMP-2/MMP-9-associated blood–brain barrier disruption and hippocampal neuronal apoptosis. Its doxycycline intervention provides pharmacological evidence that preserving barrier integrity can mitigate arsenic-related behavioral and tissue injury, while also highlighting the limits of inferring causality from a single inhibitor.

• Sodium Nitroprusside in Sex-Informed Vascular Research

  2026-08-20

  Use Sodium Nitroprusside as an endothelium-independent nitric oxide donor to separate vascular smooth muscle responsiveness from systemic, autonomic, and sex-dependent drivers of hypertension. This practical guide connects telemetry-based angiotensin II models with vessel-ring and platelet workflows, including starting parameters and troubleshooting strategies.

• Minocycline HCl in Retinal Microglia Assays

  2026-08-19

  Minocycline HCl provides a practical pharmacological control for testing whether microglial activity is required for 40-Hz flicker–associated amyloid-β clearance. This workflow connects MHC-II profiling with Aβ assays, retinal function, formulation control, and troubleshooting for reproducible neuroinflammation studies.

• Dinaciclib and VHL Loss in Clear Cell Renal Cancer

  2026-08-19

  Nelson and colleagues identified a synthetic-lethal relationship between Dinaciclib treatment and VHL deficiency in clear cell renal cell carcinoma. Their combination of cell-based assays, mechanistic readouts, and an orthotopic patient-derived xenograft model supports selective targeting of both tumor bulk and CD105-defined cancer stem-cell populations, while highlighting important limits for clinical translation.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody in Osteogenesis

  2026-08-18

  Learn how the Cy5 Goat Anti-Mouse IgG (H+L) Antibody can convert lithium-engineered exosomal Wnt10a biology into spatially resolved, reproducible fluorescence measurements. This guide focuses on assay architecture, controls, and interpretation across IHC, ICC, and flow cytometry.

• DNP-Induced seRNA Drives NPC Metastasis

  2026-08-18

  The 2023 study by Jia and colleagues identifies a carcinogen-responsive super-enhancer RNA, seRNA-NPCm, that promotes nasopharyngeal carcinoma metastasis through an NPM1/c-Myc/NDRG1 regulatory axis. Its integrated RNA-seq, GRO-seq, ChIP-seq, perturbation, animal, and patient-tissue analyses connect super-enhancer activity and R-loop-associated chromatin looping with clinically relevant metastatic behavior.

• LARP1, Ribosomes, and Repressed TOP mRNAs

  2026-08-17

  The reference study shows that LARP1 directly binds non-translating ribosomal subunits and uses a previously uncharacterized region to occlude the mRNA channel of the 40S subunit. Its structural and biochemical results separate ribosome association from LARP1-dependent TOP mRNA repression and stabilization, refining models of translational control during cellular stress.

3563 records 1/238 page Next 12345 下5页 Last page